|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008976,
umls-concept:C0030705,
umls-concept:C0036525,
umls-concept:C0087113,
umls-concept:C0600688,
umls-concept:C1123023,
umls-concept:C1274040,
umls-concept:C1522484,
umls-concept:C1527249,
umls-concept:C1556085,
umls-concept:C1707520,
umls-concept:C1825590,
umls-concept:C2697648
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2011-7-13
|
|
pubmed:abstractText |
The AIO KRK-0104 randomised phase II trial investigated the efficacy and safety of two capecitabine-based regimens: combination of capecitabine and irinotecan (CAPIRI) plus cetuximab (CAPIRI-C) and combination of capecitabine with oxaliplatin (CAPOX) plus cetuximab (CAPOX-C) in the first-line treatment of metastatic colorectal cancer (mCRC). Treatment-related skin toxicity (ST) was evaluated separately for capecitabine and cetuximab. The present analysis investigates the correlation of capecitabine-attributed ST (Cape-ST) and parameters of treatment efficacy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1532-1827
|
|
pubmed:author |
pubmed-author:AbenhardtWW,
pubmed-author:DeckerTT,
pubmed-author:DietzfelbingerHH,
pubmed-author:Fischer von WeikersthalLL,
pubmed-author:GiessenCC,
pubmed-author:HaberlCC,
pubmed-author:HassH GHG,
pubmed-author:HeinemannVV,
pubmed-author:KappaufHH,
pubmed-author:KleinSS,
pubmed-author:MittermüllerJJ,
pubmed-author:MoosmannNN,
pubmed-author:OruzioDD,
pubmed-author:PuchtlerGG,
pubmed-author:SchulzeMM,
pubmed-author:StauchMM,
pubmed-author:StintzingSS,
pubmed-author:Vehling-KaiserUU,
pubmed-author:ZellmannKK
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
12
|
|
pubmed:volume |
105
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
206-11
|
|
pubmed:meshHeading |
pubmed-meshheading:21750558-Aged,
pubmed-meshheading:21750558-Aged, 80 and over,
pubmed-meshheading:21750558-Antibodies, Monoclonal,
pubmed-meshheading:21750558-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21750558-Camptothecin,
pubmed-meshheading:21750558-Carcinoma,
pubmed-meshheading:21750558-Clinical Trials as Topic,
pubmed-meshheading:21750558-Colorectal Neoplasms,
pubmed-meshheading:21750558-Deoxycytidine,
pubmed-meshheading:21750558-Female,
pubmed-meshheading:21750558-Fluorouracil,
pubmed-meshheading:21750558-Germany,
pubmed-meshheading:21750558-Humans,
pubmed-meshheading:21750558-Incidence,
pubmed-meshheading:21750558-Male,
pubmed-meshheading:21750558-Middle Aged,
pubmed-meshheading:21750558-Neoplasm Metastasis,
pubmed-meshheading:21750558-Prognosis,
pubmed-meshheading:21750558-Skin Diseases,
pubmed-meshheading:21750558-Treatment Outcome
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial.
|
|
pubmed:affiliation |
Medical Department III, University of Munich, Klinikum Muenchen-Grosshadern, Marchioninistrasse 15, D-81377 Munich, Germany.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
